Regeneron Pharmaceuticals (REGN) – Investment Analysts’ Weekly Ratings Changes

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

  • 10/6/2026 – Regeneron Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $900.00 to $950.00. They now have an “overweight” rating on the stock.
  • 10/1/2026 – Regeneron Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $870.00 to $930.00. They now have a “buy” rating on the stock.
  • 10/1/2026 – Regeneron Pharmaceuticals was upgraded by Argus from “hold” to “buy”. They now have a $850.00 price target on the stock.
  • 9/29/2026 – Regeneron Pharmaceuticals had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $737.00 price target on the stock.
  • 9/28/2026 – Regeneron Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 9/21/2026 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
  • 9/20/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 9/12/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 9/10/2026 – Regeneron Pharmaceuticals had its price target raised by HSBC Holdings plc from $800.00 to $920.00. They now have a “buy” rating on the stock.
  • 8/17/2026 – Regeneron Pharmaceuticals had its price target raised by Leerink Partners from $641.00 to $824.00. They now have a “market perform” rating on the stock.
  • 8/15/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,946 shares of company stock valued at $3,302,458. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

Recommended Stories